Bergenbio ASA
OSE:BGBIO
Bergenbio ASA
Revenue
Bergenbio ASA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
Bergenbio ASA
OSE:BGBIO
|
Revenue
kr848k
|
CAGR 3-Years
3%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
![]() |
Hofseth Biocare ASA
OSE:HBC
|
Revenue
kr257.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
31%
|
CAGR 10-Years
29%
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Revenue
kr4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
![]() |
Arcticzymes Technologies ASA
OSE:AZT
|
Revenue
kr104.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Revenue
$8.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Bergenbio ASA
Glance View
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
See Also
What is Bergenbio ASA's Revenue?
Revenue
848k
NOK
Based on the financial report for Dec 31, 2024, Bergenbio ASA's Revenue amounts to 848k NOK.
What is Bergenbio ASA's Revenue growth rate?
Revenue CAGR 5Y
-38%
Over the last year, the Revenue growth was 140%. The average annual Revenue growth rates for Bergenbio ASA have been 3% over the past three years , -38% over the past five years .